Tags : Tislelizumab

Biotech

Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib

Shots: The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, China and Australia. Both the companies will mutually supply drug and other support Tislelizumab is an anti PD-1 mAb, specifically designed to minimize binding to […]Read More

Biotech

BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene

Shots: BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene, following the pending acquisition of Celgene by BMS In Jul’17, BeiGene granted exclusive WW rights (Ex- Asia) of tislelizumab for solid tumor and retained global rights for hematology & solid tumor in […]Read More

Pharma

BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla

Shots: BioAtla to receive $20M upfront, $249M as WW development & regulatory milestones, commercial milestones and royalties in Beigene’s territory (Asia (ex-Japan), Australia and New Zealand). Beigene to get WW co-exclusive & exclusive development & commercialization rights respectively for BioAtla’ BA3071 in combination with Beigene’s tislelizumab Beigene to take care of all development & commercialization […]Read More

Pharma

NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab

Shots:  Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical method, supply of GMP clinical material, and CMC filing support with the NMPA Boehringer claims to provide manufacturing support to BeiGene for tislelizumab for global […]Read More